Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

ctive DNA damage, irreversible G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Ovarian Cancer

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2008 there will be an estimated 21,650 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. Following frontline treatment, recurrence rates among ovarian cancer patients are high. Treatment options remain limited following relapse and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... KS (PRWEB) , ... June 29, 2015 , ... ... PATENT 7736892 B2. Under the terms of the agreement, MediVet will acquire the ... Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as a potential next-generation ...
(Date:6/29/2015)...  AACC, a global scientific and medical professional ... is pleased to announce that the impact factor ... increased to 7.9 in the 2014 Thomson Reuters ... Chemistry in the top 3% of all ... the research it publishes on laboratory medicine and ...
(Date:6/29/2015)... June 29, 2015 According to a ... XNA), by Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other ... Companies, CRO) - Global Forecast to 2020", published by MarketsandMarkets, ... by 2020 from $107.56 Million in 2015, at a CAGR ... ables and 67 F igures spread through ...
(Date:6/29/2015)... 2015   For the seventh year running, Across Health ... overall digital maturity called the Multichannel Maturometer . ... not maturing fast enough. While it,s true that technology ... overall and customers are increasingly "digital natives", pharma still ... engagement.  ...
Breaking Biology Technology:MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4
... took his computer to boot up, Klui began to think ... enormous quantities of data, but they are slow; every time ... is transferred from the hard disk into RAM (random access ... energy consumption runs into the hundreds of millions of dollars ...
... Nov. 15, 2010, PRNewswire-Asia/ -- Tiens Biotech Group (USA), Inc. (the ... www.tiens-bio.com , today announced financial results ... Revenue for the third quarter of 2010 was $10.4 ... Revenue for the nine months ended September 30, 2010 was $30.0 ...
... Celladon Corp., a biopharmaceutical company focused on ... cardiovascular diseases, today announced that 12-month data from ... demonstrated significant improvements in clinical outcomes and key ... with the genetically-targeted enzyme replacement therapy. ...
Cached Biology Technology:Racetrack memory 2Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 2Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 3Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 4Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 5Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 6Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 7Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 8Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 9Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 2Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 3Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 4
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/23/2015)... 22, 2015 Research ... of the "Body-Worn Temperature Sensors Market - ... Forecast 2014 - 2020" report to their ... of the global body-worn temperature sensors market. The ... on the basis of types, care setting, patient ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... oysters on a hot sunny afternoon? Make the most ... shown that global warming increases the sensitivity of oysters ... in polluted areas. Dr. Gisela Lannig from the University ... cadmium poisoning in eastern oysters (Crassostrea virginica) on Monday ...
... a highly effective analgesic, its clinical utility is severely ... for increasing doses to maintain analgesic effect, and the ... of Current Biology, researchers report a new study showing ... along with small doses of two versions of methadone, ...
... for viral-based therapies for cancer , Researchers at Columbia ... work to develop the next generation of effective viral-based ... with genetically engineered viruses studied in mice, published today ... the National Academy of Sciences (PNAS), bring us significantly ...
Cached Biology News:Opiate cocktail may spare cells from morphine's dark side 2Columbia scientists develop cancer terminator viruses 2Columbia scientists develop cancer terminator viruses 3